Abstract

Background: Monocytes have pro-inflammatory role; they are likely to be involved in degradation of β-cells.

Objectives: To establish the level of intermediate monocyte CD 14+ and CD16+ in patient newly diagnosed T1DM and its impact on the diagnosis and prognosis of T1DM.

Subjects and methods: This study was analytical cross-sectional study assessed at Pediatric Endocrinology Outpatient, Minia university hospital, 65 children were separated into two groups for the study: Group I (T1DM group) consisted of 40 children with recently developed T1DM, and Group II (control group) consisted of 25 children. The subjects under study underwent thorough history-taking, clinical examinations, and laboratory tests as C-peptide, HbA1c, Insulin antibodies, CBC and level of CD14+ & CD16+

Ethical Approval: The ethical council for the faculty of medicine approved this study and all measures were followed in line with the rules and legislation that applicable. All subjects provided written informed permission, and the Research Ethical Committee authorized the study. Approval No.277:1/2022

Results: Our results revealed that the proportionate of intermediate monocytes CD14+, CD16+ were considerably more in cases group compared to control group. HbA1C, RBG, 2-hr postprandial glucose, TTG IgA, IgG had markedly greater levels in the cases group in comparison to the control group. In contrast, C-peptide level was much lower in the cases group compared to the control group. Anti-GAD antibodies were reported in (77.5%) of cases while IAA were reported in(62.5%).

Conclusion: children with T1DM, the intermediate monocytes are greatly increased and contributes an essential part in the disease's etiology.